Investigational Drug Information for NNZ-2591
✉ Email this page to a colleague
What is the development status for investigational drug NNZ-2591?
NNZ-2591 is an investigational drug.
There have been 5 clinical trials for NNZ-2591.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2021.
The most common disease conditions in clinical trials are Syndrome, Hyperventilation, and Facies. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited and [disabled in preview].
There are seven US patents protecting this investigational drug and thirty-five international patents.
Summary for NNZ-2591
US Patents | 7 |
International Patents | 35 |
US Patent Applications | 10 |
WIPO Patent Applications | 6 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 1 (2021-10-01) |
Vendors | 8 |
Recent Clinical Trials for NNZ-2591
Title | Sponsor | Phase |
---|---|---|
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) | Neuren Pharmaceuticals Limited | Phase 2 |
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Neuren Pharmaceuticals Limited | Phase 2 |
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) | Neuren Pharmaceuticals Limited | Phase 2 |
Clinical Trial Summary for NNZ-2591
Top disease conditions for NNZ-2591
Top clinical trial sponsors for NNZ-2591
US Patents for NNZ-2591
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
NNZ-2591 | ⤷ Try a Trial | Cyclic G-2Allylproline in treatment of Parkinson's disease | Neuren Pharmaceuticals, Ltd. (Auckland, NZ) | ⤷ Try a Trial |
NNZ-2591 | ⤷ Try a Trial | Neuroprotective bicyclic compounds and methods for their use | Neuren Pharmaceuticals Limited (Auckland, NZ) | ⤷ Try a Trial |
NNZ-2591 | ⤷ Try a Trial | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | ⤷ Try a Trial | |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for NNZ-2591
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
NNZ-2591 | Cyprus | CY1117211 | 2023-09-03 | ⤷ Try a Trial |
NNZ-2591 | Denmark | DK1664050 | 2023-09-03 | ⤷ Try a Trial |
NNZ-2591 | European Patent Office | EP1664050 | 2023-09-03 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |